Phase 2 Malformation Clinical Trials
16 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–16 of 16 trials
Recruiting
Phase 2Phase 3
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Lymphatic Malformations
Novartis Pharmaceuticals232 enrolled56 locationsNCT05948943
Recruiting
Phase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
PIK3CA MutationVascular MalformationsPIK3CA-Related Overgrowth Spectrum (PROS)+4 more
Relay Therapeutics, Inc.277 enrolled31 locationsNCT06789913
Recruiting
Phase 2
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
PI3K Gene MutationKRAS G12DVascular Anomalies+15 more
Murdoch Childrens Research Institute50 enrolled2 locationsNCT05983159
Recruiting
Phase 2
Weekly Sirolimus Therapy
Lymphatic MalformationVenous Malformation
Medical University of South Carolina24 enrolled1 locationNCT04861064
Recruiting
Phase 2
Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)
Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)
Centre Hospitalier Universitaire Dijon20 enrolled13 locationsNCT05577754
Recruiting
Phase 2Phase 3
Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations
Cerebral AV Malformation
Fondation Ophtalmologique Adolphe de Rothschild54 enrolled1 locationNCT06264531
Recruiting
Phase 2
Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations
PediatricLymphatic Malformation
University Hospital, Lille28 enrolled2 locationsNCT03243019
Recruiting
Phase 2
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
Lymphatic Malformation
Protara Therapeutics38 enrolled10 locationsNCT05871970
Recruiting
Phase 1Phase 2
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
PIK3CA-Related Overgrowth Spectrum (PROS)PIK3CA-related Vascular Malformations (PRVM)
Haihe Biopharma Co., Ltd.141 enrolled4 locationsNCT06975618
Recruiting
Phase 2
An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations
Vascular Malformations
Xuanwu Hospital, Beijing10 enrolled1 locationNCT07037238
Recruiting
Phase 2
An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations
Brain Arteriovenous Malformations
Xuanwu Hospital, Beijing10 enrolled1 locationNCT06913725
Recruiting
Phase 2
A Study of Enalapril in Treatment of Venous Malformations
PainQuality of LifeVenous Malformation+1 more
Oslo University Hospital12 enrolled1 locationNCT06788314
Recruiting
Phase 2Phase 3
Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations
Lymphatic Malformation
West China Hospital150 enrolled1 locationNCT06673290
Recruiting
Phase 2
Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial
Intracerebral HemorrhageBrainstem StrokeCavernous Malformations
Huashan Hospital75 enrolled2 locationsNCT06091332
Recruiting
Phase 2
Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients
Lymphatic Malformation
West China Hospital200 enrolled1 locationNCT06437158
Recruiting
Phase 2
Proton Radiotherapy for Primary Central Nervous System Tumours in Adults
Central Nervous System TumourArteriovenous Malformation
Uppsala University500 enrolled6 locationsNCT02797366